Description
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.
Location: SIMR (Sacramento/Valley Area)
Please contact: SIMR@sutterhealth.org about Locally Advanced or Metastatic (pionERA)
Principal Investigator
Related Studies
Breast Cancer Chemoprevention in Primary Care at Geisinger
Investigators: External PI, Principal Investigator, Xiaowei (Sherry) Yan, PhD, MS